• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Ondanset solution for injection 2mg/ml, 4ml x 5 ampoules — Made in Greece — Free Delivery

    Ondanset solution for injection 2mg/ml, 4ml x 5 ampoules — Made in Greece — Free Delivery


    Brand: HELP SA
    Product Code: Ondanset
    Availability: In Stock
    $23.03
    Add to Cart

    Product description

    Solution for injection "Ondanset" is used for the following indications:
    • nausea and vomiting caused by cytotoxic chemotherapy and radiation therapy;
    • prevention and treatment of postoperative nausea and vomiting.

    Compound

    Active ingredient: ondansetron (1 ml of solution contains ondansetron hydrochloride dihydrate is equivalent to 2 mg of ondansetron).
    Excipients: sodium chloride; citric acid, monohydrate; sodium citrate; water for injections.

    Contraindications

    • the use of ondansetron together with apomorphine hydrochloride is contraindicated, since there have been cases of severe arterial hypotension and loss of consciousness during joint use;
    • hypersensitivity to the components of the preparation .

    Mode of application

    Nausea and vomiting caused by chemotherapy and radiation therapy
    The emetogenic potential of cancer therapy varies with dose and combination of chemotherapy and radiation regimens. The choice of the dosage regimen depends on the severity of the emetogenic effect.
    Adults. Emetogenic chemotherapy and radiation therapy The recommended intravenous or intramuscular dose of the preparation is 8 mg as a slow injection for at least 30 seconds, immediately before treatment. For the prevention of delayed or prolonged vomiting after the first 24 hours, oral or rectal administration of the preparation is recommended. Highly emetogenic chemotherapy (eg, high doses of cisplatin). The preparation can be administered as a single dose of 8 mg intravenously or intramuscularly just before chemotherapy. Doses over 8 mg (up to 16 mg) can only be used as an intravenous infusion of 50-100 ml of 0.9% sodium chloride solution or other appropriate solvent; infusion should last at least 15 minutes. A single dose of more than 16 mg should not be used. For highly emetogenic chemotherapy, 8 mg of the preparation or a lower dose does not need to be diluted and can be administered by slow intravenous or intramuscular injection (at least 30 seconds) immediately before chemotherapy, followed by twice intravenous or intramuscular administration of 8 mg after 2 and 4 hours or continuous infusion 1 mg / hour for 24 hours. The effectiveness of the preparation "Ondanset" in highly emetogenic chemotherapy can be increased by an additional single injection of dexamethasone at a dose of 20 mg before chemotherapy. For the prevention of delayed or prolonged vomiting after the first 24 hours, oral or rectal administration of the preparation is recommended.
    Children aged 6 months to 17 years In pediatric practice, the preparation "Ondanset" should be administered by infusion in 25-50 ml of 0.9% sodium chloride solution or other appropriate solvent for at least 15 minutes. The dose of the preparation can be calculated based on body surface area or body weight:
    Calculation of the dose according to the surface area of ​​the child's body. The preparation should be administered immediately before chemotherapy by a single injection at a dose of 5 mg / m2, the intravenous dose should not exceed 8 mg. After 12 hours, you can start oral administration of the preparation, which can last another 5 days. Do not exceed adult dose.
    Calculation of the dose according to the child's body weight. The preparation should be administered immediately before chemotherapy by a single injection at a dose of 0.15 mg / kg. The intravenous dose should not exceed 8 mg. On the first day, you can give two more intravenous doses at 4-hour intervals. After 12 hours, you can start oral administration of the preparation, which can last another 5 days. Do not exceed adult dose.
    Postoperative nausea and vomiting
    Adults. For the prevention of postoperative nausea and vomiting, the recommended dose of the preparation is 4 mg as a single intramuscular or slow intravenous injection during anesthesia. For the treatment of postoperative nausea and vomiting, the recommended single dose of the preparation is 4 mg in the form of intramuscular or slow intravenous injection.
    Children from one month to 17 years old. For the prevention and treatment of postoperative nausea and vomiting in children who are operated on under general anesthesia, the preparation can be administered at a dose of 0.1 mg / kg body weight (maximum up to 4 mg) by slow intravenous injection (at least 30 seconds ) before, during, after the introduction of anesthesia or after surgery.

    Application features

    Pregnant
    The safety of using the preparation during pregnancy for humans has not been established. During experimental studies on animals, the preparation did not interfere with the development of the embryo or fetus and did not affect the course of pregnancy, peri- and postnatal development. However, since animal studies are not always predictive for humans, the preparation is not recommended for use during pregnancy.
    In experimental studies, it was shown that ondansetron passes into the breast milk of animals. If necessary, use of the preparation should stop breastfeeding.
    There is no information available on the effects of ondansetron on human fertility.
    Drivers
    Psychomotor tests have shown that ondansetron does not affect the ability to drive mechanisms and does not have a sedative effect, but the side effect profile of the preparation should be borne in mind when deciding whether to drive vehicles or other mechanisms.

    Overdose

    There are insufficient data on overdose of Ondanset. In most cases, symptoms are similar to those described in patients who were given the recommended doses. Ondansetron increases the QT interval in a dose-dependent manner. In case of overdose, ECG monitoring is recommended.
    Among the manifestations of overdose, such as visual disturbances, severe constipation, arterial hypotension, vasovagal manifestations with transient atrioventricular block of II degree were reported. In all cases, these phenomena completely disappeared. There are reports of cases of serotonin syndrome in young children after taking an overdose. There is no specific antidote, therefore, in cases of overdose, symptomatic and supportive therapy should be used.
    Further management of patients should be carried out according to clinical indications or, if possible, according to the recommendations of the national center for poisoning.
    The use of ipecacuana for the treatment of ondansetron overdose is not recommended, since its effect cannot manifest itself through the antiemetic effect of the preparation "Ondanset".
    Children: Serotonin syndrome has been reported in infants and children aged 12 months to 2 years after an accidental overdose of an oral preparation (doses exceeded the recommended level of 4 mg / kg).

    Side effects

    Side effects, information about which is given below, are classified by organs and systems and by frequency of occurrence. By the frequency of occurrence, side effects are divided into the following categories: very often (≥ 1/10), often (≥ 1/100 and <1/10), infrequently (≥ 1/1000 and <1/100), rarely (≥ 1 / 10000 and <1/1000), very rarely (<1/10000).
    From the immune system: rarely - immediate-type hypersensitivity reactions, sometimes severe, up to anaphylaxis.
    From the nervous system: very often - headache; infrequently - convulsions, movement disorders (including extrapyramidal reactions such as oculogyric crisis, dystonic reactions and dyskinesia without persistent clinical consequences); rarely - dizziness, mainly during the rapid administration of the preparation.
    From the side of the organs of vision: rarely - fleeting visual disturbances (blurred eyes), mainly with intravenous administration; very rarely - transient blindness, mainly during intravenous administration (in most cases, blindness disappears within 20 minutes).
    From the side of the heart: infrequently - arrhythmia, chest pain (with or without ST segment depression), bradycardia; rarely - prolongation of the QT interval (including tremors / ventricular fibrillation (torsade de pointes)).
    From the side of the vessels: often - a feeling of warmth or hot flashes; infrequently - arterial hypotension.
    On the part of the respiratory system and chest organs: infrequently - hiccups.
    From the digestive tract: often - constipation.
    From the digestive system: infrequently - an asymptomatic increase in liver function indicators (these cases are observed mainly in patients who are treated with chemotherapy preparations containing cisplatin).
    On the part of the skin and subcutaneous tissue: very rarely - toxic rashes, including toxic epidermal necrolysis.
    From the side of the cardiovascular system: chest pain and discomfort, extrasystoles, tachycardia, including ventricular and supraventricular tachycardia, atrial fibrillation, palpitations, fainting, ECG changes.
    Hypersensitivity reactions: anaphylactic reactions, angioedema, bronchospasm, anaphylactic shock, pruritus, rash, urticaria.
    From the nervous system: gait disturbance, chorea, myoclonus, restlessness, burning sensation, protrusion of the tongue, diplopia, paresthesia.

    Storage conditions

    Store in its original packaging at a temperature not exceeding 30 ° C, out of the reach of children.
    Shelf life is 3 years.

    There are no reviews for this product.
    VEV Healthcare Store © 2017